4.07

1.75% 0.07

Diamedica Therapeutics Inc (DMAC)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Diamedica Therapeutics Inc stock is traded at $4.07, with a volume of 115.84K. It is up +1.75% in the last 24 hours and up +15.95% over the past month. DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

Previous Close:

$4.00

Open:

$3.99

24h Volume:

115.84K

Relative Volume:

1.25

Market Cap:

$174.44M

Revenue:

Net Income/Loss:

$-19.90M

P/E Ratio:

-7.6792

EPS:

-0.53

Net Cash Flow:

$-19.80M

1W Performance:

+10.30%

1M Performance:

+15.95%

6M Performance:

+1.50%

1Y Performance:

+35.22%

1-Day Range:

$3.885

$4.225

1-Week Range:

$3.61

$4.31

52-Week Range:

$2.14

$6.8184

Diamedica Therapeutics Inc Stock (DMAC) Company Profile

Name

Diamedica Therapeutics Inc

Sector

Healthcare (1147)

Industry

Biotechnology (673)

Phone

(763) 496-5454

Address

301 CARLSON PARKWAY, MINNEAPOLIS, MN

Employee

Twitter

@diamedica

Next Earnings Date

2025-03-17

Latest SEC Filings

DMAC's Discussions on Twitter

Compare DMAC with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DMAC Diamedica Therapeutics Inc	4.07	158.14M	0	-19.90M	-19.80M	-0.53
ONC Beigene Ltd Adr	225.77	25.49B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	434.38	110.32B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.32	38.69M	0	0	0	0.00
REGN Regeneron Pharmaceuticals Inc	584.99	59.13B	14.09B	4.50B	2.96B	39.28
VRNA Verona Pharma Plc Adr	69.53	5.64B	0	-153.72M	-103.81M	-2.00

Diamedica Therapeutics Inc Stock (DMAC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-07-24	Initiated	H.C. Wainwright	Buy
Apr-24-24	Resumed	Craig Hallum	Buy
Jun-22-23	Upgrade	Oppenheimer	Perform → Outperform
Apr-09-21	Initiated	Oppenheimer	Outperform
Feb-17-21	Initiated	ROTH Capital	Buy
Oct-30-20	Initiated	Guggenheim	Buy
Jul-08-20	Initiated	Maxim Group	Buy
Apr-30-19	Initiated	Dougherty & Company	Buy
Mar-05-19	Initiated	Lake Street	Buy

View All

Diamedica Therapeutics Inc Stock (DMAC) Latest News

02:11 AM

DiaMedica targets preeclampsia Phase 2 dose selection and ReMEDy2 interim analysis in H1 2026 as enrollment momentum builds - MSN

02:11 AM

01:35 AM

DiaMedica Therapeutics reports annual meeting results By Investing.com - Investing.com Canada

01:35 AM

May 15, 2025

DiaMedica Therapeutics reports annual meeting results - Investing.com

May 15, 2025

DiaMedica Elects Directors at Annual Meeting - TipRanks

May 15, 2025

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q1 2025 Earnings Call Transcript - Insider Monkey

May 15, 2025